PMID- 26171209
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 3
IP  - 4
DP  - 2015 Jul
TI  - Efficacy and adverse events of transcatheter arterial chemoembolization in 
      combination with sorafenib in the treatment of unresectable hepatocellular 
      carcinoma.
PG  - 929-935
AB  - The aim of the present study was to assess the association between the efficacy 
      and adverse events (AEs) of transcatheter arterial chemoembolization (TACE) 
      combined with sorafenib in patients with unresectable hepatocellular carcinoma 
      (HCC). Between July 2008 and May 2011, 50 patients with unresectable HCC were 
      enrolled and assigned to receive TACE combined with sorafenib in the present 
      study. The primary outcomes were considered as time to disease progression (TTP) 
      and sorafenib-related AEs. In the present study, 34 of 50 patients had disease 
      progression with a median TTP (mTTP) of 210 days. The most common AEs included 
      hand-foot skin reaction (HFSR), fatigue, diarrhea and hypertension. The mTTP of 
      patients with HFSR extended 140 days compared to that of the patients without 
      HFSR. Kaplan-Meier analysis was used for mTTP between the two groups of patients. 
      This difference was statistically significant when analyzed by the univariate COX 
      proportional hazards regression model. In conclusion, TACE in combination with 
      sorafenib had an acceptable safety profile in the treatment of unresectable HCC. 
      Additionally, it also revealed that HFSR served as a good prognostic predictor in 
      using combination therapy. Therefore, discontinuation of sorafenib treatment 
      should be prevented to avoid disease progression.
FAU - Yao, Xuesong
AU  - Yao X
AD  - Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical 
      Science, Peking Union Medical College, Beijing 100005, P.R. China.
FAU - Yan, Dong
AU  - Yan D
AD  - Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical 
      Science, Peking Union Medical College, Beijing 100005, P.R. China.
FAU - Liu, Dezhong
AU  - Liu D
AD  - Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical 
      Science, Peking Union Medical College, Beijing 100005, P.R. China.
FAU - Zeng, Huiying
AU  - Zeng H
AD  - Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical 
      Science, Peking Union Medical College, Beijing 100005, P.R. China.
FAU - Li, Huai
AU  - Li H
AD  - Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical 
      Science, Peking Union Medical College, Beijing 100005, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20150424
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC4486900
OTO - NOTNLM
OT  - adverse events
OT  - efficacy
OT  - hepatocellular carcinoma
OT  - sorafenib
OT  - transcatheter arterial chemoembolization
EDAT- 2015/07/15 06:00
MHDA- 2015/07/15 06:01
PMCR- 2015/04/24
CRDT- 2015/07/15 06:00
PHST- 2014/12/04 00:00 [received]
PHST- 2015/04/08 00:00 [accepted]
PHST- 2015/07/15 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/07/15 06:01 [medline]
PHST- 2015/04/24 00:00 [pmc-release]
AID - MCO-0-0-554 [pii]
AID - 10.3892/mco.2015.554 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2015 Jul;3(4):929-935. doi: 10.3892/mco.2015.554. Epub 2015 Apr 
      24.